Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) was the target of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 4,850,000 shares, a growth of 100.4% from the August 15th total of 2,420,000 shares. Based on an average daily trading volume, of 1,560,000 shares, the days-to-cover ratio is currently 3.1 days. Currently, 14.0% of the shares of the stock are short sold.
Several large investors have recently modified their holdings of PLX. XTX Topco Ltd purchased a new position in Protalix BioTherapeutics in the 2nd quarter worth approximately $33,000. Credit Suisse AG purchased a new position in shares of Protalix BioTherapeutics during the 1st quarter valued at approximately $45,000. Virtu Financial LLC purchased a new position in shares of Protalix BioTherapeutics during the 1st quarter valued at approximately $124,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Protalix BioTherapeutics during the 2nd quarter valued at approximately $126,000. Finally, Laurion Capital Management LP purchased a new position in shares of Protalix BioTherapeutics during the 1st quarter valued at approximately $191,000. Institutional investors and hedge funds own 10.43% of the company’s stock.
Shares of PLX stock opened at $1.32 on Friday. Protalix BioTherapeutics has a twelve month low of $1.30 and a twelve month high of $7.02. The stock has a market capitalization of $60.14 million, a P/E ratio of -2.64 and a beta of 2.67.
About Protalix BioTherapeutics
Protalix Biotherapeutics, Inc is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.
Featured Article: What is an Initial Coin Offering (ICO)?
Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.